1. IL-12 primed CD8+ T-cells possess enhanced persistence and anti-tumor efficacy because of greater IL-7 responsiveness. (7th November 2013) Authors: Johnson, C Bryce; May, Bennett R; Cloud, Colleen A; Rubinstein, Mark P; Cole, David J Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗